GlobeNewsWire
23 Jun 2026, 19:52 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Prestige Consumer Healthcare's North America OTC Eye & Ear Care segment experienced a 20.6% year-over-year revenue decrease in Q4 2026. — A significant revenue collapse in a core business segment indicates severe operational failure and lost market share.
-0.70The company's International OTC segment reported a 31.3% year-over-year revenue decrease for Q4 2026. — Deep declines across multiple geographies suggest systemic issues rather than localized market fluctuations.
-0.60The Pillar5 facility, intended to resolve supply chain constraints for the Clear Eyes brand, has suffered from recurring and expanding production shutdowns. — Failure of a strategic acquisition to fix supply issues undermines the company's primary recovery thesis.
-0.50Continue reading
6 related stories
Search tags
Law firm Hagens Berman has opened an investigation into whether Prestige misled investors regarding the Pillar5 facility's performance and supply chain remediation. — Legal investigations into securities fraud create overhang and the risk of costly class-action settlements.
-0.30Which stocks this story touches
The company experienced significant revenue declines, production problems, and is facing a shareholder investigation for potential securities law violations.
Mentioned as having a stock plunge due to allegedly misleading financial statements.
Mentioned as having a stock plunge due to allegedly misleading financial statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
